

Occasional essay: upper motor neuron syndrome in amyotrophic lateral sclerosis

Article (Accepted Version)

Swash, Michael, Burke, David, Turner, Martin R, Grosskreutz, Julian, Leigh, P Nigel, deCarvalho, Mamede and Kiernan, Matthew C (2020) Occasional essay: upper motor neuron syndrome in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, 91 (3). pp. 227-234. ISSN 0022-3050

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/89267/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

The upper motor neuron syndrome in amyotrophic lateral sclerosis

Michael Swash, David Burke, Martin R Turner, Julian Grosskreutz, P Nigel Leigh, Mamede de Carvalho and Matthew C Kiernan

Affiliations:

MS: Barts and the London School of Medicine, QMUL, London UK; and Instituto de Medicina Molecular, Faculdade de Medicina, Univeridade de Lisboa

DB: University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

MRT: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

MCK: University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

PNL: Trafford Centre for Biomedical Research, Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, Brighton UK

JG: Universitätsklinikum Jena, Friedrich-Schiller-University Jena, Jena, Germany

MdeC: Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Univeridade de Lisboa, and Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte. Lisbon, Portugal

Funding acknowledgements: MCK receives funding support from the National Health and Medical Research Council of Australia Program Grant (#1132524), Partnership Project (#1153439) and Practitioner Fellowship (#1156093). PNL is supported by funding from: The European Union H2020 Program (Grant No 633413); The MND Association; The Dunhill Trust; The Wellcome Trust. JG is supported by the Dt. Gesellschaft für Muskelkranke (DGM).

Correspondence: mswash@btinternet.com

Word count: 4474

Abstract word count: 164

References: 153 *Tables:* 1 *Illustrations:* 1

Introduction

The diagnosis of amyotrophic lateral sclerosis (ALS) requires recognition of both lower (LMN) and upper motor neuron (UMN) dysfunction.¹ However, classical UMN signs are frequently difficult to identify in ALS.² LMN involvement is sensitively detected by electromyography (EMG)³ but, as yet, there are no generally accepted markers for monitoring UMN abnormalities,⁴ the neurobiology of ALS itself, and disease spread through the brain and spinal cord.⁵ Full clinical assessment is therefore necessary to exclude other diagnoses and to monitor disease progression. In part, this difficulty regarding detection of UMN involvement in ALS derives from the definition of ‘the UMN syndrome’. Abnormalities of motor control in ALS require reformulation within an expanded concept of the UMN, together with the neuropathological, neuro-imaging and neurophysiological abnormalities in ALS. We review these issues here.

The Lower Motor Neuron

Sir Charles Sherrington (1857-1952) defined the LMN^{6,7} as the anterior horn cell and its motor axon, constituting the final common pathway for reflex action.⁸ In 1906 Sherrington,⁷ following Hughlings Jackson’s insights, concluded that motor acts were initiated in the brain by sensory input, thus building on activation of this simple reflex pathway, a view further developed by Sir Francis Walshe (1885-1973).⁹ Merton et al¹⁰ likened the effect of reflex action to a follow-up length servo, an influential hypothesis, that was subsequently modified as servo assistance to emphasize that stretch reflexes support movement, generated centrally, rather than drive it.^{11,12} Despite these ideas, the UMN syndrome is not well defined.^{7,13-15}

The Upper Motor Neuron

The clinical criteria (Table 1) used by generations of neurologists to define the ‘corticospinal’ or ‘pyramidal’ syndrome, a term frequently but erroneously regarded as synonymous with ‘UMN syndrome’, rest on surprisingly uncertain pathophysiological underpinnings. The term UMN was introduced by Sir William Gowers (1845-1915) in his *Manual of Neurology*¹³ published before Sherrington’s work.¹⁴ Later, the anatomist, Alf Brodal (1910-1988), emphasized that the UMN¹⁶ consists not just of corticospinal fibres but of all those fibres with motor functions that descend through the pyramids in the lower brainstem on each side. The UMNs therefore include crossed and uncrossed corticospinal tracts (CST), corticobulbar,

tectospinal, rubrospinal, vestibulospinal and reticulospinal tracts, as well as various short internuncials and cerebellar connexions.¹⁵⁻¹⁷ The CSTs constitute only 2-3% of fibres in the pyramidal UMN pathway.¹⁸ They provide direct connexions between Betz ‘giant’ cells in primary motor cortex and anterior horn cells in the anterior spinal grey matter and also, through corticobulbar connexions, to neurons in the bulbar motor nuclei. This corticospinal projection consists of large diameter ($>10\mu\text{m}$), thickly myelinated, monosynaptic, fast-conducting motor efferents. However, most fibres passing caudally through the pyramids are much smaller, $<4\mu\text{m}$ in diameter.^{9,18} The majority of fibres in the medullary pyramids have indirect, polysynaptic projections to spinal interneurons and motoneurons. In addition to the well-known monosynaptic corticomotoneuronal projection, in cat, macaque and humans corticospinal axons have disynaptic projections to upper-limb motoneuron pools through propriospinal neurons located in the C3-C4 levels. This relay allows the corticospinal command to be modulated before it reaches segmental level through a combination of feedback from the moving limb and feedforward inhibition from supraspinal centres. Within these diverse efferent motor projections there are additional descending fibres derived widely from the cerebral cortex, including sensory cortex, that also project to interneurons and primary motor neurons in the anterior horns of the cord, as well as to sensory neurons in the dorsal horn. These descending projections modulate both sensory input to the cord and its motor output.¹⁹ In summary, the grey matter of the spinal cord is a busy place and much of what goes on there is not under direct voluntary control. This is consistent with the semi-automatic nature of rapid object grasping. As Lemon¹⁹ summarised: ‘the descending pathways function as part of a large network rather than as separate controllers of the spinal cord’ and ‘the spinal cord functions as part of the brain not as its servant’. The clinical terms “pyramidal syndrome” or “UMN syndrome” conceal a complex motor system.^{9,15}

The clinician’s corticospinal syndrome

Hughlings Jackson²⁰ made detailed studies of the clinical features of hemiplegia in stroke. He drew attention not only to negative features, such as loss of strength and orienting responses, but also to positive features, such as increased muscular tone, and a brisk knee jerk. The Babinski response was incorporated later (Table 1).²¹⁻²³ In hemiplegia Jackson recognized residual, voluntary limb motor function and characteristic resting limb and body postures. For these and other reasons, especially those related to his observation of the ‘march of focal epilepsy’, he concluded that movements were represented in cerebral cortex and muscles in spinal segments, a view that remains generally accepted.²⁴ Modern descriptions of lesions

ascribed to the pyramidal pathway emphasize weakness, loss of dexterity, slowness and poverty of hand movements, brisk tendon reflexes, a spastic increase in muscle tone and the extensor plantar response (Table 1). Spasticity and weakness do not necessarily coexist, and probably relate to dysfunction in different pathways. Denny-Brown and Botterell²⁵ found that ablation of Brodmann cortical area 4 in the macaque led to flaccid hemiparesis, followed in a few days by increased tendon jerks and hypertonus of distal limb segments, whereas ablation of Brodmann area 6 caused a more widespread hypertonus resembling the clinician's 'extrapyramidal rigidity'.²⁵ However, in the macaque, Fulton described spasticity, hemiparesis and apraxia after area 6 ablation.²⁶ Much therefore depends on the site and extent of any lesion in the motor system; and also on the ability of researchers to examine primates as fully as human subjects. Walshe⁹ reviewed these and earlier experiments, including early ablation studies in primates,²⁷ and studies of electrical stimulation of the cerebral cortex in humans.²⁸ He drew the important conclusions that cortical electrical stimulation was likely to be dependent on the characteristics of the stimulation technique, a factor difficult to quantify.⁹

Tower²⁹ found that section of the pyramid at the medullary level in monkey caused a 'grave and general poverty of movement' and initial hypotonia. Fine, discrete movements were lost and there was impairment of aim and precision of movement performance, i.e., poverty of movement with loss of dexterity. In the chimpanzee, but not in the monkey, a Babinski reflex could be elicited and there was increased proprioceptive grasping in the upper limb. In searching for methods to alleviate Parkinsonian tremor, Bucy^{30,31} surgically sectioned the human ipsilateral cerebral peduncle. There was less resultant paresis than anticipated and remarkable recovery occurred, but with persistent impairment of fine manipulative finger and hand movement. Electrical stimulation of the uninjured peduncle delineated a medial fronto-pontine bundle, associated with hand and forearm movements, and a more lateral temporo-pontine tract. Mid or upper cervical pyramidotomy, as reported by Lassek et al³² for surgical alleviation of tremor, caused paralysis below the site of the lesion that gradually improved, with considerable residual impairment of upper limb movements, weakness of foot dorsiflexion, increased tendon reflexes and a Babinski response.³²

The functions of the complex motor pathways at brainstem level were addressed by Lawrence and Kuypers in their now-classic primate experiments.³³⁻³⁵ After bilateral pyramidotomy at olivopontine level that interrupted the corticospinal pathway from cortical

area 4, climbing behaviour, as an example of whole body movement, was largely intact, but there was impaired speed and fluency. There was loss of dexterity of hands and digits in retrieving food rewards and isolated actions, such as reaching and grasping, were also severely and permanently affected. Subsequent interruption of the ventromedial descending motor pathway in the medial reticular formation in the floor of the fourth ventricle, consisting of descending fibres from the tectum, the pontine and medullary medial reticular formation and the vestibular complex, caused loss of righting responses, impaired unsupported sitting, walking and climbing and of head, shoulder and trunk movement, but without loss of automatic hand grasping. Lesion of the magnocellular rubrospinal fibres in the lateral medullary brainstem pathway that project to the dorso-lateral zones of the spinal anterior horns, caused loss of ipsilateral hand movements, with a persistent posture of flexion of the arm and extension of the fingers. Bilateral pontine lesions caused similar abnormalities.

Lawrence and Kuypers' work confirmed that the brain motor system consists of much more than the CST and the primary motor cortex.^{33,34} They concluded that the ventromedial brainstem pathways are the basic system by which the brain controls bodily movement, maintenance of posture, and integration of body-limb movements and locomotion, while the lateral brainstem pathway confers the ability to superimpose independent movements of the extremities, especially the hand, and the corticospinal pathways facilitate further fractionation of movement, especially finger movements. The lateral CSTs project to the intermediate internuncial zone of ventral spinal grey matter, linked to motor neurons innervating muscles of the distal extremities. Corticospinal neurons originating in M1 project directly to these spinal motor neurons, and to the ventromedial intermediate zone controlling trunk and limb-girdle muscles. In addition, some fibres in the CSTs originate in the primary somatosensory cortex and terminate in the spinal dorsal horn.

Single corticomotoneurons and their pyramidal tract axons project to multiple muscles in the primate upper-limb, though usually with a stronger projection to one muscle – stronger and more widespread to extensor muscles than flexors, and stronger distally than proximally.³⁶ There may be plasticity at the corticomotoneuronal synapse, since connectivity is altered by movement in primates,³⁷ and segmental interneurons are active during voluntary movement³⁸

As in the cat,³⁹ and the macaque,⁴⁰ in human subjects the CST projects to upper cervical propriospinal neurons which then relay some of the corticospinal command to upper limb

motor neurons.^{41,42} This allows updating of the motor command by sensory feedback from the moving limb.⁴³ There seem to be no such projections to the intrinsic muscles of the hand.

The UMN deficit in ALS

The UMN features (Table 1) in ALS are not typical of the classic UMN syndrome (Table 1). For example, the plantar responses may be downgoing, even in the presence of other classical UMN features.² UMN lesions cause loss of the local extensor reflexes, such as the plantar reflex response, and also the abdominal and cremasteric reflexes, and disinhibition of the flexion withdrawal response, manifested by activation of extensor hallucis longus and therefore a dorsiflexor (extensor) Babinski toe response,⁴⁴ but this will depend on the force exerted by these opposing reflex systems, which may be disrupted by the motor network disorder in ALS. In ALS there is widespread involvement of the UMN² beyond the archetypal corticospinal lesion familiar from internal capsular infarction.^{16,20} Attribution of components of the motor syndrome in ALS specifically to UMN or LMN dysfunction is difficult since both are usually present. LMN features often predominate and spasticity and increased reflexes may be subtle.² The progressive pattern of LMN weakness and atrophy in ALS suggests relatively orderly spread from a clinical site of origin,⁴⁵ perhaps representing spread by contiguity in spinal segments,^{46,47} but 'skip lesion' weakness and atrophy also occur,^{48,49} and a CNS origin for these phenomena has been proposed.⁵⁰

Kinnier Wilson⁵¹ taught that flexor muscles are earlier and more severely affected than extensors, although long extensors of the forearm are weakened before long flexors. In the hand the abductor pollicis brevis and first dorsal interosseous muscles are particularly susceptible but the abductor digiti minimi is relatively spared. This 'split hand'⁵² has been linked to the dense corticospinal innervation of the more susceptible muscles⁵³ associated with their importance in thumb movement and grasping,⁵⁰ but this pattern of wasting is inconstant and other, perhaps related, explanations are possible.⁵⁴ The motor syndrome in ALS includes abnormalities of stance and balance, and of foot placement, sometimes with features consistent with loss of orienting reflexes.⁵⁵ Hand and finger movement is often markedly affected, with loss of dexterity and slowness of movement, sometimes described as clumsiness, in addition to objective weakness of grasp and other hand and finger movements. The gait is also clumsy and unreactive to barriers, as in managing ambulation over a rough surface. When there is bulbar involvement the normal precise coordination of respiratory pattern, voice, speech, swallowing, saliva management, and facial movement is impaired

causing degradation and coarseness of all these functions. These deficits result from degeneration of small-fibre propriospinal rather than corticospinal motor pathways and their central network connections, as shown by the Lawrence and Kuypers experiments described above.

Higher-order functional motor deficits in ALS

Loss of dexterity is a well-recognised feature of the “UMN syndrome” in stroke.⁵⁶ When the corticospinal tract is damaged, recovery of the function of intrinsic muscles of the hand is less reliant on oligosynaptic corticospinal and other descending inputs, because they are the only upper-limb muscles to receive an exclusively monosynaptic (and lateralised) corticospinal input.⁴² In his textbook Kinnier Wilson commented on prominent ‘awkwardness of fine finger movements’ in the early stages of ALS, despite only slight weakness and the absence of spasticity.⁵¹ This forgotten observation suggests a higher-order motor defect, or apraxia, associated with frontotemporal cortical atrophy and the associated tract degeneration that characterize the CNS disorder in ALS and ALS-FTLD. Higher-order motor deficits are particularly evident in behavioural variant FTLT, manifest by motor slowness and loss of intuitive, complex patterns of voluntary movement, and dominated by a prominent frontal executive syndrome with frontal and prefrontal cortical atrophy, with or without an associated ALS syndrome.

The term apraxia has not been applied to the motor disorder in ALS perhaps because this extends the concept of apraxia beyond its classical definition as a higher-order motor disorder in the absence of focal neurological signs, especially weakness or sensory loss.^{57,58} However, in modern usage, apraxia, due to loss of specialised cortical function from focal lesion or degeneration, has been termed ‘hodological apraxia’, and disconnection syndromes due to fibre tract degeneration, ‘topological apraxia’.⁵⁹ Cortical and pathway lesions may induce increased or decreased excitability in the damaged motor system.⁵⁹ Recognition of higher-level motor disturbances in ALS extends understanding of the UMN or central motor dysfunction. ALS patients require marked effort to achieve adequate velocity and precision of movement, but retain ability to visualize and describe motor components necessary to perform fine graduated movements. Thus, the core features of ideomotor apraxia are absent, in ALS^{57,58} although they may be recognisable in ALS-FTLD. In ALS, the cortical disorder and secondary motor tract degeneration cause disconnection of the cerebral motor systems from the spinal cord motor systems, including propriospinal motor connections and

proprioceptive control mechanisms. Disruption and slowness of movement in ALS results both from degeneration in descending motor pathways and loss of control mechanisms; for example, connexions to basal ganglia and cerebellum that normally fine tune the motor drive.

Neuropathology of the UMN in ALS

Pathological studies of the CNS in ALS are inevitably limited to end-stage disease. The first descriptions of cellular pathology in the motor cortex and subcortical motor pathways derive from Marie who, with Charcot, described ‘atrophy of the large pyramidal cells of the cortex’, loss of these cells, and ‘numerous granular bodies’ in the subcortical white matter, interpreted as degenerating corticofugal fibres.^{60,61} Degeneration of corticofugal fibres was traced through the internal capsule into the cerebral peduncles, the medullary pyramids and spinal cord, but was not seen at a higher level,⁶²⁻⁶⁴ in contrast to the pattern of degeneration following vascular lesions of the motor cortex in which the process progressed caudally - a ‘dying forward’ process.⁶⁰ Marie therefore dismissed the notion that in ALS degeneration of the CST proceeds caudally from the motor cortex to the spinal cord, in parallel with loss of spinal motor neurons: “Unfortunately, gentlemen, this seductive theory very imperfectly explains the morbid process which produces amyotrophic lateral sclerosis and serious objections may be made to its adoption”.⁶⁰ This puzzle remains unresolved⁶⁵ but is consistent with emerging concepts of ALS as a network connectivity disorder.

There is variable loss of pyramidal neurons in ALS, particularly Betz cells, in the primary motor cortex and surrounding areas.^{63,64,66-69} but cerebral pathology is not solely restricted to the primary motor cortex.^{7,64} In ALS-FTLD syndromes there is marked frontal atrophy; with neuronal loss in layers 2, 3 and 5, ‘status spongiosus’, astrogliosis, and microglial proliferation as co-indicators of widespread pathology. At autopsy abnormalities in ALS are widespread in central motor pathways. REF Loss of pyramidal neurons in layers 4 and 5 of the primary motor cortex, and of cortical peptidergic and GABAergic interneurons⁷⁰⁻⁷¹ is controversial,⁷² but loss of pyramidal cells and interneurons extends to cortical areas 4, 9 and 24. Loss of cortical pyramidal neurons and interneurons in distant, indirectly connected cortical areas is consistent with the notion that ALS and FTLD are related anterior brain degenerations,. Selective susceptibility of long axons, as a concept,⁷³ has been superseded by the notion of vulnerability of functionally related neuronal and glial networks, associated with TDP43 deposits in remaining neurons. It is difficult to correlate clinical phenotype with motor or frontal cortical or CST pathology in ALS.⁶³⁻⁶⁶ Indeed, in progressive muscular

atrophy (PMA) despite little or no clinical evidence of UMN involvement there is almost universal pathological evidence of CST degeneration,^{74,75} perhaps clinically undetectable due to the extent of LMN loss and muscle atrophy.

Overall, therefore, the pathological evidence points towards a process of axonal degeneration. Occasionally MRI reveals striking signal change in the cerebral CSTs⁷⁶ but whether or not this represents Wallerian degeneration, a progressive anterograde degeneration of axons in reaction to injury, is unclear.^{77,782} However, blocking the molecular pathways that contribute to Wallerian degeneration does not modulate neurodegeneration in mouse ALS models.⁷⁹ Neuronal cell bodies and axons in CNS motor pathways seem to be involved together..

Intracellular inclusions containing ubiquitin, p62, and abnormal TDP-43 are far less marked in cortical motor neurons than in somatic motor neurons of the brain stem and spinal cord, or in neurons in layers 2, 3 and 5 in the prefrontal and temporal regions in FTLN and ALS-FTLN. Altered TDP-43 probably drives degeneration in the CST. Abnormalities in Betz cells and pyramidal cells of the primary motor cortex in sporadic and familial ALS, and in ALS-FTLN, include fragmentation, vacuolation, and atrophy of apical dendrites, loss of spines, apical dendrite retraction and loss of postsynaptic densities.⁸⁰⁻⁸³ Studies in animal models suggest that dendritic pathology is an early, indeed pre-symptomatic, feature of ALS⁸⁴⁻⁸⁶ and that TDP-43 cytoplasmic mislocalisation is associated with reduction in dendritic spine density.⁸⁶² How far these observations mirror the evolution of pathology in human ALS is uncertain.⁸⁷ In summary, there is incomplete understanding of the dynamics of UMN degeneration in ALS.⁶⁵ Genetic heterogeneity, and the wide variation in the distribution and burden of UMN pathology across the ALS and ALS-FTLN syndromes, suggests marked variability in the underlying dynamic processes, even in clinically similar ALS syndromes.⁸⁸

Structural biochemistry of the UMN in ALS

Neurofilaments (NFs) are components of the neuronal cytoskeleton, classified by molecular weight into light chain (NfL), heavy chain (NfH) and intermediate chain. Raised CSF and blood levels have been demonstrated in many CNS diseases, correlated with the clinical intensity and presumably reflecting the rate of neuronal and axonal loss.⁸⁹ In the earliest reports of raised CSF NF levels seen in ALS, it was noted that levels were highest in those with UMN signs.^{90,91} This was replicated in larger patient series, in which a strong relationship to rate of increasing disability was confirmed.⁹² The assumption that high CSF

levels in ALS reflect CST damage was tested using paired diffusion tensor imaging measures, but the results showed limited⁵ or no apparent association.⁹³ Additional CSF and blood-based studies have reported only weak distinction between NF levels and clinical UMN versus LMN involvement in ALS.^{94,95}

Imaging in ALS: widespread UMN abnormalities

Macroscopic *post mortem* cerebral atrophy is strikingly limited in ALS. Localized, ‘knife-edge’ atrophic pre-central gyri are seen in slowly progressive cases, especially in Primary Lateral Sclerosis, a syndrome in which degeneration is clinically limited to the UMN.⁹⁶ Automated volumetric MRI studies in ALS may detect diffuse frontal cerebral atrophy, especially associated with cognitive impairment⁹⁷⁻⁹⁹ but there is currently only limited evidence supporting somatotopic motor cortical atrophy in relation to regional motor disability.^{99,100} In some patients there is hyperintensity in the CSTs in T2-weighted MRI,¹⁰¹ but with weak clinical correlation.¹⁰² However, T2-based MRI signal analysis, using diffusion tensor imaging (DTI), has confirmed consistent loss of CST integrity more consistently related to classic clinical UMN involvement.¹⁰³ Linkage of primary motor cortical atrophy and clinical UMN signs is strengthened by MR spectroscopy, using reduced N-acetylaspartate levels as a surrogate marker for neuronal loss, both in region-of-interest¹⁰⁴ and whole-brain studies.¹⁰⁵ Interhemispheric motor cortical fibres in the central corpus callosum (Fig 1) are consistently involved in ALS,^{106,107,108} especially in PLS.^{109,110} DTI changes correlate with clinical and transcortical magnetic stimulation studies of UMN involvement.^{107,109,111} and Wallerian degeneration with microglial infiltration has been suggested as correlates of these white matter tract MRI changes.^{112,113}

White matter tract damage in ALS (Fig 1) is invariably bilateral in DTI studies and extends far beyond the pyramidal tracts and the corpus callosum, even in patients studied soon after the onset of focally restricted symptoms.¹¹⁴ Structural studies focused beyond the cortical grey matter in ALS have shown associated changes in basal ganglia,⁹⁹ particularly in the thalami - points of integration with widespread frontotemporal cortical involvement in the course of the disease.¹¹⁵ MRI has confirmed the neuropathological finding that in progressive muscular atrophy (PMA) there is typically also sub-clinical degeneration of the pyramidal pathway.^{74,75}

Neuroimaging markers and disability in ALS are poorly correlated, reflecting dependence of the ALS Functional Rating Scale on LMN loss.¹¹⁶ Functional brain imaging with positron emission tomography (PET), using radiotracers sensitive to glucose metabolism and blood flow has also demonstrated brain changes beyond primary motor regions.^{117,118} Blood flow PET during performance of a focused upper limb task revealed cortical activation extending to facial areas of the motor cortex, implying an alteration in local circuit neurophysiology, whether compensatory or a primary pathological process.¹¹⁹ Subsequent ligand PET studies using Flumazenil as a marker of GABAergic inhibitory receptors showed loss of binding in motor and premotor regions in ALS, but with relative preservation in familial slowly-progressive ALS.¹²⁰ Combined DTI and functional MRI studies provide limited support for a more direct role of inhibitory interneuron loss in the pathogenesis of ALS, rather than a solely compensatory process¹²¹ and MR spectroscopy has provided limited evidence for reduced GABA-ergic influence within the primary motor cortex.¹²²

Functional MRI based on regional patterns of synchronously fluctuating blood oxygenation level-dependent (BOLD) signal in the task-free, so-called resting state, has revealed a network-based dysfunction underlying neurodegenerative disorders more broadly,¹²³ but also to ALS.¹²⁴ Resting state network abnormalities, in the form of increased functional connectivity, are detectable in asymptomatic carriers of penetrant ALS-causing genetic variants.¹²⁵ Further, the unique temporal sensitivity of magnetoencephalography in demonstrating differences in beta-band cortical oscillations associated with the preparation, execution and recovery from motor activity¹²⁶ promises to be potentially powerful for studies of corticomuscular coherence in analysing broader motor system ‘connectome’ dysfunction in ALS.¹²⁷

Neurophysiological studies of the UMN in ALS

Early studies used transcranial electrical stimulation of the motor cortex.¹²⁸ This induced depolarization of large pyramidal neurons, and showed absent or delayed cortical responses, confirming that the fast conducting UMN tract was damaged in this disorder.¹²⁹⁻¹³¹ The central conduction time was found to be more frequently delayed in patients with UMN signs¹²⁹ and this test was more sensitive than clinical assessment in the identification of UMN dysfunction.¹²⁹⁻¹³¹ Transcranial magnetic stimulation¹³² (TMS), which superseded electrical brain stimulation, induces an intracortical current causing a transmembrane ionic flow that induces preferential transsynaptic excitation of pyramidal cells.¹³³ Motor cortical dysfunction,

related to clinical findings, is detectable in ~70% of ALS patients,¹³⁴ and in ~30% of those with pure LMN presentations.^{134,135} In addition, in early ALS the cortical motor threshold is reduced in strong muscles, in particular in those with fasciculations.¹³⁴⁻¹³⁸ Short interval intracortical inhibition (SICI), 1-4ms, measured using a paired stimulus technique is mediated by GABA-ergic (GABA-A) interneuronal circuits, and is reduced in ALS.^{139,140} An automated cortical threshold tracking technique, recording decreased motor amplitude in the target muscle¹⁴¹ has shown that this is a consistent early marker of ALS, and that it precedes clinical onset in SOD1 familial ALS. Furthermore, this abnormality is partially normalized by riluzole.¹⁴² Peri-stimulus time histogram studies in early affected patients showed increased magnitude of EPSPs.¹⁴³ Fasciculations, a typical marker of LMN dysfunction in ALS, can sometimes be evoked by TMS,¹⁴⁴ probably representing LMN hyperexcitability.

Spasticity, a feature of the classical UMN syndrome, is a sign of alpha-corticomotoneuronal hyperexcitability.³⁹ This membrane change is associated with stable membrane potentials (plateau potentials), that resist changes in response to peripheral inputs,¹⁴⁵ shown by analyzing the variability of the LMN firing rate in ALS and PLS.¹⁴⁶ The cortical silent period (CSP), mainly representing cortical inhibition,¹⁴⁷ is a period of EMG silence during muscle contraction following a motor response evoked by TMS. It tends to be shorter in ALS, especially early in disease progression.¹⁴⁸ The H-reflex, mirroring the monosynaptic tendon-reflex, is abnormal consistent with clinical signs of UMN involvement, especially in analyses of the slope angle of its earliest rising phase.¹⁴⁹ These changes are consistent with coupled UMN-LMN hyperexcitability. However, adapted interneuronal responses in the spinal cord resulting from reduced corticospinal input, leading to increased compensatory alpha-motoneuron hyperexcitability are also a possible mechanism.¹⁵⁰ Hyperexcitability may be an early feature of neuronal degeneration but, also, a transitory adaptive process to compensate for neuronal loss, although the latter seems less likely.^{151,152} Current neurophysiological methods do not address function in most of the ancillary UMN pathways, as reviewed above, that have a critical role in the disease process. In addition, the role of spinal cord UMN pathways, an integral component of the CNS, is not well defined.

Conclusions

ALS is a disorder characterised by anterior brain neurodegeneration, that seems to result from interactions between genetic and potential environmental risk factors, with striking clinical variability.⁸⁸ Recognition of the UMN abnormality in ALS has always been difficult,

despite its importance for robust diagnosis.^{1,3,4} This reflects diagnostic emphasis on the classical clinical signs of internal capsular lesions as the epitome of the UMN syndrome. However, in ALS, frontal brain degeneration is widespread, with complex secondary efferent and commissural tract degenerations diffusely involving the brain motor network and its related connections. Involvement of other brain structures, including thalamic¹²³ and cerebellar changes,¹⁵³ and the anterior horns in the spinal cord,² and frontal cognitive abnormalities, is consistent with this concept of anterior brain degeneration. In ALS and ALS-FTLD classical UMN features, as seen in focal brain lesions, are overwhelmed by anterior horn cell and interneuronal degeneration in the spinal cord,² and by higher-order functional motor deficits. The latter have been underestimated by ALS clinicians. Expansion of the concept of the UMN deficit in the ALS syndrome, including structural and functional brain imaging and neurophysiological assessment of cortical and deep white matter motor systems will facilitate understanding of the functional deficits. Given the pathophysiological complexity of the UMN syndrome it is not surprising that the full clinical syndrome is often not present in ALS, underlying the need for surrogate markers of UMN dysfunction. A wider concept of the UMN syndrome in ALS is required.

References

1. Brooks BR and World Federation of Neurology sub-Committee on Motor Neuron Diseases. El Escorial World Federation of Neurology criteria for diagnosis of amyotrophic lateral sclerosis. *J Neurol Sci.* 1994;124:965–1085
2. Swash M. Why are upper motor neuron signs so difficult to elicit in amyotrophic lateral sclerosis? *J Neurol Neurosurg Psychiatry* 2012;83:659-66
3. de Carvalho M, Swash M. Awaji algorithm increases sensitivity of El Escorial diagnostic criteria in ALS diagnosis. *Amyotroph Lat Sclerosis* 2008;10:53-7
4. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J, Swash M. Electrodiagnostic criteria for diagnosis of ALS: Consensus of an International Symposium sponsored by IFCN, December 3-5 2006, Awaji-shima, Japan. *Clin Neurophysiol* 2008;119:407-503
5. Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. *Ann Clin Transl Neurol* 2015;2:748-55
6. Liddell EGT, Sherrington CS. Recruitment and some other features of reflex inhibition. *Proc Roy Soc* 1925;97B:488-518
7. Sherrington CS. *Integrative Action of the Nervous System.* New Haven. Yale University Press. 1906:1-411
8. Sherrington CS. The correlation of reflexes and the principle of the common path. *Brit Ass Rep* 1904;74:728-41
9. Walshe FMR. *Critical Studies in Neurology.* Edinburgh. E & S Livingstone. Chapters I-V. 1948:3-237
10. Merton PA (1953) Speculations on the servo-control of movement, in *The Spinal Cord*, Ciba Foundation Symposium, ed. Wolstenholme GEW, pp. 247-60, Churchill, London.
11. Marsden CD, Merton PA, Morton HB. (1972) Servo action in human voluntary movement. *Nature* 238: 140–3.
12. Merton PA. Neurophysiology in man. *J Neurol Neurosurg Psychiatry* 1981;44:861-70
13. Gowers W. *A Manual of Diseases of the Nervous System.* London. J&A Churchill. 1886
14. Sherrington CS. The mammalian spinal cord as an organ of reflex function. *Philos Trans Roy Soc* 1898;190B:45-186 (see also abstract of Croonian Lecture in *Proc Roy Soc* 1897;61:220-1
15. Phillips CG, Landau WM. Upper and lower motor neuron; the little old synecdoche that works. *Neurology* 1990;40:884-6
16. Brodal A. *Neurological Anatomy in Relation to Clinical Medicine.* Oxford. Oxford University Press, 1981:180-293.

17. Holstege G. Somatic motoneurons and descending motor pathways: limbic and no-limbic components. In PN Leigh and M Swash (Eds), *Motor Neuron Disease; Biology and management*. London. Springer-Verlag. 1995:259-330
18. Lassek AM The human pyramidal tract. IV. A study of the mature, myelinated fibers of the pyramid. *J Comp Anat* 1942;76:217-25
19. Lemon RN. Descending pathways in motor control. *Ann Rev Neurosci* 2008;31:195-218
20. Jackson JH. Two lectures on hemiplegia. *Lond Hosp Reports* 1865;1::297-312 and 313-32
21. Babinski MJ. Sur la reflexe cutanée plantaire dans certaines affections organiques de la système nerveux centrale. *CR Soc Biol* 1896;48:207-8
22. Nathan PW, Smith MC. The Babinski response: a review and new observations. *J Neurol Neurosurg Psychiat* 1955;18:250-9
23. Wilkins RH, Brody IA. Babinski's sign. *Arch Neurol* 1967;17:441-5
24. Grillner S, Hallgren J, Menard A, Saitoh K, Wilkinson MA. Mechanisms for selection of basic motor programs: roles for the striatum and pallidum. *Trends Neurosci* 2005;28:304-70
25. Denny-Brown D, Botterell EH. The motor functions of the agranularfrontal cortex. *Proc Assoc Res Nerv Ment Dis* 1948; 27: 235–345.
26. Fulton JF. A note on the definition of the 'frontal' and 'prefrontal' motor areas. *Brain* 1935;58:311-16
27. Leyton ASF, Sherrington CS. Observations on the excitable motor cortex of the chimpanzee, orang-utang and gorilla. *Q J Physiol* 1917;11:135-222
28. Penfield W, Boldrey E. Somatic motor and sensory representation in the cerebral cortex of man as studied by electrical stimulation. *Brain* 1937;60:389-443
29. Tower SS. Pyramidal lesion in the monkey. *Brain* 1940;63:36–90
30. Bucy PC. Is there a pyramidal tract? *Brain* 1957;80:376-92
31. Bucy PC, Keplinger JE, Siqueira JA. Destruction of the 'pyramidal tract' in man. *J Neurosurg* 1964;21:385-98
32. Lassek AM, Woolsey CN, Walker AE, Boshes B. Symposium of Inquiry: The pyramidal tract (moderator, Augustus Rose). *Neurology* 1957;7:496-509
33. Lawrence DG, Kuypers HGJM. The functional organization of the motor system in the monkey. I. The effects of bilateral pyramidal lesions. *Brain* 1968;91:1-14
34. Lawrence DG, Kuypers HGJM. The functional organization of the motor system in the monkey. II. The effects of lesions of the descending brain-stem pathway. *Brain* 1968;91:15-36
35. Lemon RN, Landau W, Tutsell D, Lawrence DG. Lawrence and Kuypers (1968a,b) revisited: copies of the original filmed material from their classic papers in *Brain*. *Brain* 2012;135:2290-95
36. Fetz EE, Cheney PD. Postspike facilitation of forelimb muscle activity by primate corticomotoneuronal cells. *J Neurophysiol*. 1980;44:751-72

37. Nishimura Y, Perlmuter SI, Eaton RW, Fetz EE. Spike-timing-dependent plasticity in primate corticospinal connections induced during free behavior. *Neuron*. 2013;80:1301-9
38. Perlmuter SI, Maier MA, Fetz EE. Activity of spinal interneurons and their effects on forearm muscles during voluntary wrist movements in the monkey. *J Neurophysiol*. 1998;80:2475-94
39. Lundberg A. Descending control of forelimb movements in the cat. *Brain Res Bull* 1999;50:323-24
40. Kinoshita M, Matsui R, Kato S, Hasegawa T, Kasahara H, Isa K, Watakabe A, Yamamori T, Nishimura Y, Alstermark B, Watanabe D, Kobayashi K, Isa T. Genetic dissection of the circuit for hand dexterity in primates. *Nature* 2012;487:235-38.
41. Pierrot-Deseilligny E. Propriospinal transmission of part of the corticospinal excitation in humans. *Muscle Nerve* 2002;26:155-72.
42. Pierrot-Deseilligny E, Burke D. *The Circuitry of the Human Spinal Cord: Spinal and Corticospinal Mechanisms of Movement*. Cambridge University Press: New York, 2012;606pp.
43. Tohyama T, Kinoshita M, Kobayashi K, Isa K, Watanabe D, Kobayashi K, Liu M, Isa T. (2017) Contribution of propriospinal neurons to recovery of hand dexterity after corticospinal tract lesions in monkeys. *Proc Natl Acad Sci USA* 2017;114: 604-9
44. Kugelberg, E, Eklund, K, Grimby, L. (1960). An electromyographic study of the nociceptive reflexes of the lower limb. Mechanism of the plantar responses.
45. Swash M. Vulnerability of lower brachial myotomes in motor neurone disease: clinical and EMG studies, *J Neurol Sci* 1980;47:59-68
46. Swash M, Leader M, Brown A, Swettenham K. Focal loss of anterior horn cells in the cervical cord in motor neurone disease. *Brain* 1986;109:939-52
47. Ravits JM, LaSpada AR. ALS phenotype heterogeneity, focality and spread: deconstructing motor neuron disease. *Neurology* 2009;73:805-811
48. Sekiguchi T, Kanouchi T, Noto Y, Yagi Y, Inaba A, Abe K et al. Spreading of amyotrophic lateral sclerosis – multifocal hits and local spread. *J Neurol Neurosurg Psychiatry* 2014;85:85-91
49. Swash M. How does ALS spread between neurons in the CNS. *J Neurol Neurosurg Psychiatry* 2013;84:116-117
50. Eisen A, Kuwabara S. The split hand syndrome in ALS. *J Neurol Neurosurg Psychiatry* 2012;83:399-403
51. Wilson SAK. Amyotrophic lateral sclerosis. In *Neurology*. London, Edward Arnold. 1940; Chapter 54:1007-1032
52. Wilbourn AJ. The 'split hand' syndrome. *Muscle Nerve* 2000;23:138
53. Kuwabara S, Sonoo M, Komori T, Shinnan T, Hirashima F, Inaba A et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent and specificity. *Muscle Nerve* 2008;37:426-430

54. De Carvalho M, Swash M. The split hand in amyotrophic lateral sclerosis: a role for the neuromuscular junction. *Amyotroph Lat Scler Fronto Temporal Degen* 2019;20:368-375
55. Desai J, Swash M. Extrapyrmidal involvement in ALS: backward falls and retropulsion. *J Neurol Neurosurg Psychiatry* 1999;67:214-216
56. Burke D, Wissel J, Donnan GA. Pathophysiology of spasticity in stroke. *Neurology* 2013;80(suppl 2):S20-S26
57. Leiguarda R. Apraxias as traditionally defined. In Freund H-J, Jeannerod M, Hallett M, Leiguarda R (Eds) *Higher-order motor disorders: from neuroanatomy and neurobiology to clinical neurology*. Oxford, Oxford University Press. 2005;Chapter 17:303-338
58. Liepmann H. Das Krankheitsbild der Apraxie (motorische Asymbolie) auf Grund eines Falles von einseitiger Apraxie. *Monatsschr Psychiat Neurol* 1900;8:15-44, 102-132, 182-197
59. Catani M, ffytche DH. The rises and falls of disconnection syndromes. *Brain* 2005;128:2224-2239
60. Marie, P. *Lectures on Diseases of the Spinal Cord*. New Sydenham Society, London, Lecture XXXVIII. Amyotrophic Lateral Sclerosis. 1885. 467-474.
61. Charcot JM, Marie P. Deux Nouveau cas de la sclérose amyotrophique latérale suivis d'autopsie. *Arch Neurol* 1885;101-135, 168-186.
62. Bertrand L, Van Bogaert L. La Sclérose Amyotrophique Latérale (anatomie pathologique). *Rev Neurol* 1925;32:779-806.
63. Davison C. Amyotrophic Lateral Sclerosis: origin and extent of the upper motor neuron lesion. *Arch Neurol Psychiat* 1941;46:1039-1056.
64. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neuron disease. *J Neurol Neurosurg Psychiatry* 1970;33:338-357.
65. Baker MR. ALS – dying forward, backward or outward? *Nat Rev Neurol* 2014;10:660
66. Lawyer T Jr, Netsky MG. Amyotrophic lateral sclerosis: a clinico-anatomic study of 53 cases. *Arch Neurol* 1953;69:171-193.
67. Smith M. Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 1960;23:269-282.
68. Martin J, Swash M. Alternative Approaches to the Pathology of Motor Disease. In: Leigh PN and Swash M. *Motor Neuron Disease: Biology and Management* . Springer–Verlag, London. 1985;119-161.
69. Chou S. Pathology of Motor System Disorder. In: Leigh PN and Swash M. *Motor Neuron Disease: Biology and Management* Springer–Verlag, London. 1995;pp 53-92.
70. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. *Acta Neuropathol* 1993;86:55-64.
71. Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, Everall I, Leigh PN. Cortical selective vulnerability in motor neuron disease: a morphometric study. *Brain*. 2004;127:1237-51.

72. Gredal O, Pakkenberg H, Karlsborg M, Pakkenberg B. Unchanged total number of neurons in motor cortex and neocortex in amyotrophic lateral sclerosis: a stereological study. *J Neurosci Methods* 2000;95:171-6.
73. Cavanagh JB. The problems of neurons with long axons. *Lancet* 1984;1:1284-7.
74. Ince PG, Evans J, Knopp M, Forster G, Hamdalla HH, Wharton SB, Shaw PJ. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. *Neurology* 2003;60:1252-1258.
75. Rosenbohm A, Muller HP, Hubers A, Ludolph AC, Kassubek J. Corticoefferent pathways in pure lower motor neuron disease: a diffusion tensor imaging study. *J Neurol* 2016;263:2430-7
76. Ellis C, Simmons A, Dawson JM, Williams SC, Leigh PN. Distinct hyperintense, MRI signal changes in the corticospinal tracts of a patient with motor neuron disease. *Amyotroph Lateral Scler Other Motor Neuron Disord* 1999;1:41-4.
77. Adalbert R, Coleman MP. Review: Axon pathology in age-related neurodegenerative disorders. *Neuropathol Appl Neurobiol* 2013;39:90-108.
78. Yaron A, Schuldiner O. Common and Divergent Mechanisms in Developmental Neuronal Remodeling and Dying Back Neurodegeneration. *Curr Biol* 2016;26:R628-R639
79. Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. *Nat Rev Neurosci* 2014;15:394-409
80. Hammer RP, Tomiyasu U, Scheibel AB (1979). Degeneration of the Human Betz Cell in Amyotrophic Lateral Sclerosis. *Experimental Neurology* 63:336-346.
81. Horoupian DS, Thal L, Katzman R, Terry RD, Davies P, Hirano A, DeTeresa R, Fuld PA, Petito C, Blass J, et al. (). Dementia and motor neuron disease: morphometric, biochemical, and Golgi studies. *Ann Neurol* 1984;16:305-13
82. Ferrer I. Neurons and their Dendrites in Frontotemporal Dementia. *Dement Geriatr Cogn Disord* 10(suppl) 1999;1:55-60
83. Genç B, Jara JH, Lagrimas AK, Pytel P, Roos RP, Mesulam MM, et al. Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS. *Sci Rep.* 2017;7:srep41765.
84. Jara JH, Villa SR, Khan NA, Bohn MC, Ozdinler PH. AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALS. *Neurobiol Dis* 2012;47:174-83.
85. Fogarty MJ, Klenowski PM, Lee JD, Driberg-Thompson JR, Bartlett SE, Ngo ST, Hilliard MA, Bellingham MC, Noakes PG. Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. *Sci Rep* 2016;9;6:37968
86. Handley EE, Pitman KA, Dawkins E, Young KM, Clark RM, Jiang TC, Turner BJ, Dickson TC, Blizzard CA. Synapse Dysfunction of Layer V Pyramidal Neurons Precedes Neurodegeneration in a Mouse Model of TDP-43 Proteinopathies. *Cerebr Cortex* 2017;27:3630-3647
87. Broad RJ, Gabel MC, Dowell NG, Schwartzman DJ, Seth AK, Zhang H, Alexander DC, Cercignani M, Leigh PN. Neurite orientation and dispersion density imaging (NODDI) detects

- cortical and corticospinal tract degeneration in ALS. *J Neurol Neurosurg Psychiatry*. 2019;90:404-11.
88. Brown RH Jr, Al-Chalabi A. Amyotrophic Lateral Sclerosis. *N Engl J Med*. 2017;377:162-172 and 1602(letter)
 89. Olsson B, Portelius E, Cullen NC, Sandelius A, Zetterborg H, Andreasson U et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease and movement disorders. *JAMA Neurol* 2019;76:318-25
 90. Rosengren LE, Karlsson JE, Karlsson JP, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in cerebrospinal fluid. *J Neurochem* 1996;67:2013-18
 91. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tomani H. Axonal damage markers are increased in amyotrophic lateral sclerosis. *Neurology* 2006;66:852-56
 92. Lu CH, MacDonald-Wallis C, Gray E, Pearce N, Petzold A, Norgen A et al. Neurofilament light chain: a prognostic biomarker of amyotrophic lateral sclerosis. *Neurology* 2015;84:2247-57
 93. Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbigbauer S et al.. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2019;90:157-161
 94. Feneberg E, Oeckl P, Steinacker O, Verde F, Barro C, van Damme P et al. Multicenter evaluation of neurofilaments in early symptomatic onset amyotrophic lateral sclerosis. *Neurology* 2018;90:e22-230 PMID 29212830
 95. Poesen K, de Schepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S et al. Neurofilament markers for amyotrophic lateral sclerosis correlate with extent of upper and lower motor neuron disease. *Neurology* 2017;88:2302-2309
 96. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. *Brain* 1992;115:495-520
 97. Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. *Neurology*. 2005;65:75-80
 98. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T. Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. *BMC Neurol* 2006;6:17
 99. Schuster C, Kasper E, Dyrba M, Machts J, Bittner D, Kaufmann J, et al. Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis. *Neurobiology of aging*. 2014;35:240-6
 100. Bede P, Bokde A, Elamin M, Byrne S, McLaughlin RL, Jordan N, et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. *J neurol Neurosurg Psychiatry*. 2013;84:766-73

101. Goodin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. *Ann Neurol*. 1988;23:418-20
102. Fabes J, Matthews L, Filippini N, Talbot K, Jenkinson M, Turner MR. Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis. *Acad Radiol*. 2017;24:1187-94
103. Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. *Neurology*. 1999;53:1051-8
104. Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. *Neurology*. 1994;44:1933-8
105. Stagg CJ, Knight S, Talbot K, Jenkinson M, Maudsley AA, Turner MR. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. *Neurology*. 2013;80:610-5
106. Kassubek J, Unrath A, Huppertz HJ, Lule D, Ethofer T, Sperfeld AD, et al for the World Federation of Neurology Research Group on Motor Neuron Diseases. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. *Amyotroph Lat Scler other Motor Neuron Disord*.. 2005;6:213-20
107. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. *Neurology*. 2010;75:1645-52
108. Probst M. Zur Kenntnis der amyotrophischen Lateralsklerose. *S-B Akad Wiss Wien*. 1903;112:683-824
109. Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, Kwak S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. *Neurology*. 2008;70:528-32
110. Agosta F, Galantucci S, Riva N, Chio A, Messina S, Iannaccone S, et al. Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. *Human brain mapping*. 2014;35:1710-22
111. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. *Brain* 2004;127:340-50
112. Cardenas AM, Sarlls JE, Kwan JY, Bageac D, Gala ZS, Danielian LE, et al. Pathology of callosal damage in ALS: An ex-vivo, 7 T diffusion tensor MRI study. *NeuroImage Clinical*. 2017;15:200-8
113. Pallebage-Gamarallage M, Foxley S, Menke RAL, Huszar IN, Jenkinson M, Tendler BC, et al. Dissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology. *BMC Neurosci* 2018;19:11
114. Menke RA, Korner S, Filippini N, Douaud G, Knight S, Talbot K et al. Widespread grey matter pathology dominates the longitudinal cerebral and clinical landscape of amyotrophic lateral sclerosis. *Brain* 2014;137:2546-55

115. Tu S, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A et al. Regional thalamic marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2018;89:1250-58
116. Verstraete E, Turner MR, Grosskreutz J, Filippi M, Benatar M. Mind the gap: the mismatch between clinical and imaging metrics in ALS. *Amyotroph Lat Scler Frontotemporal Degen.* 2015;16:524-9
117. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. *Ann Neurol* 1987;22:580-6
118. Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. *JAMA Neurol.* 2014;71:553-61
119. Kew JJ, Leigh PN, Playford ED, Passingham RE, Goldstein LH, Frackowiak RS, et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. *Brain* 1993;116:655-80
120. Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. *Brain* 2005;128:1323-9
121. Douaud G, Filippini N, Knight S, Talbot K, Turner MR. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. *Brain* . 2011;134:3470-9
122. Foerster BR, Callaghan BC, Petrou M, Edden RA, Chenevert TL, Feldman EL. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. *Neurology* 2012;78:1596-600
123. Seeley WW, Crawford RK, Zhou J, Miller BL, Griecius MD. Neurodegenerative diseases target large-scale brain networks. *Neuron* 2009;62:42-52
124. Eisen A, Turner MR. Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level? *Amyotrophic Lat Scler Frontotemporal Degener.* 2013;14:487-93
125. Menke RA, Proudfoot M, Wu J, Andersen PM, Talbot K, Benatar M, Turner MR. Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. *J Neurol, Neurosurg Psychiatry* 2016;87:580-8
126. Proudfoot M, Rohenkohl G, Quinn A, Colclough GL, Wu J, Talbot K et al. Altered beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. *Hum Brain Mapp* 2017;38:237-54
127. Proudfoot M, van Ede F, Quinn A, Colclough GL, Wu F, Talbot K et al. Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. *Clin Neurophysiol* 2018;129:1479-89
128. Merton PA, Morton HB. Stimulation of the cerebral cortex in the intact human subject. *Nature* 1980; 285:227
129. Ingram DA, Swash M. Central motor conduction is abnormal in motor neuron disease. *J Neurol Neurosurg Psychiatry.* 1987; Feb 1;50:159-66

130. Berardelli A, Inghilleri M, Formisano R, Accornero N, Manfredi M. Stimulation of motor tracts in motor neuron disease. *Journal of Neurology, Neurosurgery & Psychiatry* 1987;50:732-7;
131. Hugon J, Lubeau M, Tabaraud F, Chazot F, Vallat JM, Dumas M. Central motor conduction in motor neuron disease. *Ann Neurol.* 1987;22:544-6.
132. Barker AT, Freeston IL, Jalinous R, Jarratt JA. Clinical evaluation of conduction time measurements in central motor pathways using magnetic stimulation of human brain. *Lancet.* 1986;327:1325-6.
133. Schriefer TN, Hess CW, Mills KR, Murray NM. Central motor conduction studies in motor neurone disease using magnetic brain stimulation. *Electroencephalogr Clin Neurophysiol/Evoked Potentials Section.* 1989;74:431-7
134. Eisen A, Shytbel W, Murphy K, Hoirch M. Cortical magnetic stimulation in amyotrophic lateral sclerosis. *Muscle & Nerve* 1990;13:146-51
135. Triggs WJ, Menkes D, Onorato J, Yan RH, Young MS, Newell K, Sander HW, Soto O, Chiappa KH, Cros D. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. *Neurology* 1999;53:605-11.
136. Caramia MD, Cicinelli P, Paradiso C, Mariorenzi R, Zarola F, Bernardi G, Rossini PM. 'Excitability' changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. *Electroencephalogr Clin Neurophysiol/Evoked Potentials Section.* 1991;81:243-50
137. Desiato MT, Caramia MD. Towards a neurophysiological marker of amyotrophic lateral sclerosis as revealed by changes in cortical excitability: Distinguishing characteristics of amyotrophic lateral sclerosis by using cortical stimulation. *Electroencephalogr Clin Neurophysiol/Electromyography and Motor Control* 1997;105:1-7
138. Eisen A, Pant B, Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. *Can J Neurol Sci* 1993;20:11-16.
139. Yokota T, Yoshino A, Inaba A, Saito Y. Double cortical stimulation in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 1996;61:596-600.
140. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with ALS: Evidence from paired transcranial magnetic stimulation. *Neurology* 1997;49:1292-8.
141. Vucic S, van den Bos M, Menon P, Howells J, Dharmadasa T, Kiernan MC. Utility of threshold tracking transcranial magnetic stimulation in ALS. *Clin Neurophysiol Pract.* 2018;3:164-172
142. Vucic S, Lin CS, Cheah BC, Murray J, Menon P, Krishnan AV, Kiernan MC. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. *Brain* 2013;136:1361-70.
143. Kohara N, Kaji R, Kojima Y, Mills KR, Fujii H, Hamano T, Kimura J, Takamatsu N, Uchiyama T. Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation.

- Electroencephalogr Clin Neurophysiol/Electromyography and Motor Control. 1996;101:32-41.
144. de Carvalho M, Miranda PC, Luís MD, Ducla-Soares E. Neurophysiological features of fasciculation potentials evoked by transcranial magnetic stimulation in amyotrophic lateral sclerosis. *J Neurol* 2000;247:189-94.
 145. Floeter MK, Zhai P, Saigal R, Kim Y, Statland J. Motor neuron firing dysfunction in spastic patients with primary lateral sclerosis. *J Neurophysiol* 2005;94:919-27.
 146. de Carvalho M, Turkman A, Swash M. Motor unit firing in amyotrophic lateral sclerosis and other upper and lower motor neuron disorders. *Clin Neurophysiol* 2012;123:2312-8.
 147. Chen R, Lozano AM, Ashby P. Mechanism of the silent period following transcranial magnetic stimulation evidence from epidural recordings. *Experim Brain Res* 1999;128:539-42.
 148. Siciliano G, Manca ML, Sagliocco L, Pastorini E, Pellegrinetti A, Sartucci F, Sabatini A, Murri L. Cortical silent period in patients with amyotrophic lateral sclerosis. *J Neurol Sci* 1999;169:93-7.
 149. Simon NG, Lin CS, Lee M, Howells J, Vucic S, Burke D, Kiernan MC. Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. *Clin Neurophysiol*. 2015;126:828-36.
 150. Sangari S, Iglesias C, El Mendili MM, Benali H, Pradat PF, Marchand-Pauvert V. Impairment of sensory-motor integration at spinal level in amyotrophic lateral sclerosis. *Clin Neurophysiol*. 2016;127:1968-77.
 151. Fisher KM, Zaimi B, Williams TL, Baker SN, Baker MR. Beta-band intermuscular coherence: a novel biomarker of upper motor neuron dysfunction in motor neuron disease. *Brain*. 2012;135:2849-64.
 152. Proudfoot M, van Ede F, Quinn A, Colclough GL, Wu J, Talbot K, Benatar M, Woolrich MW, Nobre AC, Turner MR. Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. *Clin Neurophysiol* 2018;129:1479-89.
 153. Schmahmann JD, Weilburg JB, Sherman JC. The neuropsychiatry of the cerebellum – insights from the clinic. *Cerebellum* 2007;6:254-267

Table 1: Classical clinical features of upper and lower motor neuron syndromes

Note that these traditional criteria do not include any higher-order functional tests in the case of UMN disorders, which could distinguish fronto-temporal cerebral dysfunction from limited lesions in the CSTs in the brainstem or spinal cord. Internal capsular lesions frequently involve non-corticospinal descending pathways, in addition to the corticospinal pathways themselves.

Clinical sign	UMN syndrome	LMN syndrome
weakness	“pyramidal” distribution; i.e. hip flexor and foot dorsiflexor predominant	focal or multifocal, often in peripheral nerve or root distribution
loss of distal dexterity	present	absent if no sensory loss
slowness and simplification of movement	present	absent
poor balance responses	present	absent
fatigue	present	present
muscular atrophy	slight or absent	prominent in weak muscles
muscular tone	increased with spasticity	reduced in weak muscles
deep tendon and superficial reflexes	tendon reflexes increased Superficial reflexes diminished	tendon reflexes reduced or absent superficial reflexes normal or reduced
Babinski response (and related responses)	present	absent
fasciculation	absent	present

Fig 1: Diffusion Tensor Imaging (DTI) in ALS

DTI is a non-invasive, in vivo application of MRI that is sensitive to a reduction in unidirectional water movement associated with the loss of large white matter tract integrity arising through a variety of brain pathologies. In ALS, there is a consistent reduction in a quantifiable metric known as fractional anisotropy, that is most consistently spatially localised to the caudal CST and interhemispheric motor fibres of the corpus callosum (marked on the images here in yellow and orange over the background DTI white matter tract skeleton, shown in green).

